According to a latest study, very few patients who were hospitalized for heart failure and participating in a quality improvement registry seemed to have received a guideline-recommended treatment of heart failure. This suggested treatment is known as aldosterone antagonist therapy.
Clinical trials are believed to have recognized the benefits of aldosterone antagonist therapy in patients with heart failure (HF). For this reason, this therapy appears to have been chosen as ‘useful and recommended’ within the American College of Cardiology/American Heart Association (ACC/AHA) Chronic HF Guidelines.
Moreover